Phase II Trial of Exemestane in Combination With Fulvestrant in Postmenopausal Women With Advanced, Hormone-Responsive Breast Cancer

INTRODUCTION: Exemestane, the irreversible steroidal aromatase inhibitor, and fulvestrant, the pure estrogen antagonist, are active as single drugs in postmenopausal women with advanced hormone-responsive breast cancer. We designed a phase II study with the purpose of determining whether combining t...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Cyhoeddwyd yn:Clin Breast Cancer
Prif Awduron: Mrózek, Ewa, Layman, Rachel, Ramaswamy, Bhuvaneswari, Schaaf, Larry, Li, Xiaobai, Ottman, Susan, Shapiro, Charles L.
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: 2012
Pynciau:
Article
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC5003403/
https://ncbi.nlm.nih.gov/pubmed/22444722
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.clbc.2012.01.003
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg